07.15.25 -- 7 New MHRA Guidances To Help You With Decentralized Manufacturing For Cell And Gene Therapies

Breakthroughs in CAR T-cell and stem cell therapies depend on mastering cellular collection. Understanding these fundamentals is vital for advancing treatment efficacy and patient outcomes.

The material and packaging requirements for CGT are undoubtedly unique. Uncover how platforms are being established to support the specific needs of this industry. 

Optimize your protein purification workflow with tangential flow filtration by comparing membrane performance and exploring how protein concentration impacts flux and MWCO selection.

Unlock the potential of perfusion for pluripotent stem cell cultures. Explore key insights into achieving improved consistency and quality in your medium exchange protocols, leading to better outcomes.

Review the implementation of a holistic Contamination Control Strategy (CCS). Discover four key considerations for assessing component readiness: product, process, protection, and proof.

By increasing recombinant AAV titers, this AAV enhancer can help reduce upstream manufacturing costs and lower the cost per therapeutic dose.

This study demonstrates the automated magnetic isolation of CD4/CD8+ cells from fresh or frozen leukapheresis using a functionally closed cell processing system paired with a modular application.

Explore the reasoning behind the increasing demand for cleanroom technology as well as the advantages modular cleanroom design brings to the sterile processing of complex therapies.